Literature DB >> 29378179

Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors.

Maria Buur Nordskov Gabe1, Alexander Hovard Sparre-Ulrich2, Mie Fabricius Pedersen3, Lærke Smidt Gasbjerg4, Asuka Inoue5, Hans Bräuner-Osborne3, Bolette Hartmann6, Mette Marie Rosenkilde7.   

Abstract

GIP(3-30)NH2 is a high affinity antagonist of the GIP receptor (GIPR) in humans inhibiting insulin secretion via G protein-dependent pathways. However, its ability to inhibit G protein-independent signaling is unknown. Here we determine its action on arrestin-recruitment and receptor internalization in recombinant cells. As GIP is adipogenic, we evaluate the inhibitory actions of GIP(3-30)NH2 in human adipocytes. Finally, we determine the receptor selectivity of GIP(3-30)NH2 among other human and animal GPCRs. cAMP accumulation and β-arrestin 1 and 2 recruitment were studied in transiently transfected HEK293 cells and real-time internalization in transiently transfected HEK293A and in HEK293A β-arrestin 1 and 2 knockout cells. Furthermore, human subcutaneous adipocytes were assessed for cAMP accumulation following ligand stimulation. Competition binding was examined in transiently transfected COS-7 cells using human 125I-GIP(3-30)NH2. The selectivity of human GIP(3-30)NH2 was examined by testing for agonistic and antagonistic properties on 62 human GPCRs. Human GIP(3-30)NH2 inhibited GIP(1-42)-induced cAMP and β-arrestin 1 and 2 recruitment on the human GIPR and Schild plot analysis showed competitive antagonism with a pA2 and Hill slope of 16.8 nM and 1.11 ± 0.02 in cAMP, 10.6 nM and 1.15 ± 0.05 in β-arrestin 1 recruitment, and 10.2 nM and 1.06 ± 0.05 in β-arrestin 2 recruitment. Efficient internalization of the GIPR was dependent on the presence of either β-arrestin 1 or 2. Moreover, GIP(3-30)NH2 inhibited GIP(1-42)-induced internalization in a concentration-dependent manner and notably also inhibited GIP-mediated signaling in human subcutaneous adipocytes. Finally, the antagonist was established as GIPR selective among 62 human GPCRs being species-specific with high affinity binding to the human and non-human primate (Macaca fascicularis) GIPRs, and low affinity binding to the rat and mouse GIPRs (Kd values of 2.0, 2.5, 31.6 and 100 nM, respectively). In conclusion, human GIP(3-30)NH2 is a selective and species-specific GIPR antagonist with broad inhibition of signaling and internalization in transfected cells as well as in human adipocytes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antagonist; GIP receptor; Glucose-dependent insulinotropic polypeptide (GIP); Human subcutaneous adipocytes; Signaling

Mesh:

Substances:

Year:  2018        PMID: 29378179     DOI: 10.1016/j.bcp.2018.01.040

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

Review 1.  Endosomal trafficking in metabolic homeostasis and diseases.

Authors:  Jerome Gilleron; Anja Zeigerer
Journal:  Nat Rev Endocrinol       Date:  2022-10-10       Impact factor: 47.564

Review 2.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

Review 3.  GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.

Authors:  Jens Juul Holst; Mette Marie Rosenkilde
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

4.  Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.

Authors:  Piotr A Mroz; Brian Finan; Vasily Gelfanov; Bin Yang; Matthias H Tschöp; Richard D DiMarchi; Diego Perez-Tilve
Journal:  Mol Metab       Date:  2018-12-05       Impact factor: 7.422

Review 5.  Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment.

Authors:  Sine Paasch Schiellerup; Kirsa Skov-Jeppesen; Johanne Agerlin Windeløv; Maria Saur Svane; Jens Juul Holst; Bolette Hartmann; Mette Marie Rosenkilde
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-26       Impact factor: 5.555

6.  A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.

Authors:  Noura Al-Zamel; Suleiman Al-Sabah; Yunus Luqmani; Lobna Adi; Siby Chacko; Tom Dario Schneider; Cornelius Krasel
Journal:  Int J Mol Sci       Date:  2019-07-19       Impact factor: 5.923

7.  Dissecting the roles of GRK2 and GRK3 in μ-opioid receptor internalization and β-arrestin2 recruitment using CRISPR/Cas9-edited HEK293 cells.

Authors:  Thor C Møller; Mie F Pedersen; Jeffrey R van Senten; Sofie D Seiersen; Jesper M Mathiesen; Michel Bouvier; Hans Bräuner-Osborne
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

8.  GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats.

Authors:  Wijnand J C van der Velden; Florent X Smit; Charlotte B Christiansen; Thor C Møller; Gertrud M Hjortø; Olav Larsen; Sine P Schiellerup; Hans Bräuner-Osborne; Jens J Holst; Bolette Hartmann; Thomas M Frimurer; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-19

9.  Arrestin-independent constitutive endocytosis of GPR125/ADGRA3.

Authors:  Katja Spiess; Sofie O Bagger; Lola J Torz; Kristian H R Jensen; Anna L Walser; Jone M Kvam; Ann-Sofie K Møgelmose; Viktorija Daugvilaite; Riia K Junnila; Gertrud M Hjortø; Mette M Rosenkilde
Journal:  Ann N Y Acad Sci       Date:  2019-10-29       Impact factor: 5.691

10.  Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.

Authors:  Francis S Willard; Jonathan D Douros; Maria Bn Gabe; Aaron D Showalter; David B Wainscott; Todd M Suter; Megan E Capozzi; Wijnand Jc van der Velden; Cynthia Stutsman; Guemalli R Cardona; Shweta Urva; Paul J Emmerson; Jens J Holst; David A D'Alessio; Matthew P Coghlan; Mette M Rosenkilde; Jonathan E Campbell; Kyle W Sloop
Journal:  JCI Insight       Date:  2020-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.